Immune System News and Research

RSS

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, today announced that it has begun enrolling patients in a Phase 2 clinical trial of its lead compound, JVRS-100, as an adjuvant for seasonal influenza vaccines in the elderly population.

2 Nov 2009

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

WCMC-Q's biomedical research program makes significant progress

The biomedical research program of Weill Cornell Medical College in Qatar has made significant progress in its dual goals of advancing basic science and building a sustainable research community in Qatar since it was launched less than a year and a half ago.

2 Nov 2009

Bacteria use a well-studied communication system to resist antibiotics

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

1 Nov 2009

Scientists report a major step forward in the development of an effective therapy against Nipah virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

31 Oct 2009

Four abstracts on RSV and influenza prevention in pediatric health to be presented

MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Women may need smaller dose of H1N1 vaccine

THE emergence of the H1N1 swine flu has added urgency to what has become an annual ritual for millions of Americans: getting a flu shot. The good news is that scientists have developed a vaccine against the H1N1 virus. But it is taking much longer than expected to produce the hundreds of millions of doses the government had planned to distribute. And it is still too soon to know how effective the vaccine will be in preventing swine flu.

31 Oct 2009

Research suggests the possibility of an effective treatment for Hendra virus infections in humans

A scientific team from CSIRO and the US has demonstrated that administering human monoclonal antibodies after exposure to Nipah virus, which is closely related to Hendra virus, protected animals from challenge in a disease model.

31 Oct 2009

Public concern can undermine flu vaccination campaigns

The effectiveness of pandemic flu vaccination campaigns - like that now underway for H1N1 - could be undermined by the public incorrectly associating coincidental and unrelated health events with the vaccines.

31 Oct 2009

Recent releases in Global Health

"Action always leads to reaction, a fundamental law of nature," write the authors of an introduction appearing in a Journal of Acquired Immune Deficiency Syndromes (JAIDS) supplemental issue that focuses on global health systems.

30 Oct 2009

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

The Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-years, one of the high risk groups for contracting the H1N1 (swine) flu, and recommend this population receive the H1N1 vaccine for immunity against the disease.

30 Oct 2009

Scientists present new perspective on antigenic drift of flu viruses

Influenza viruses evade infection-fighting antibodies by constantly changing the shape of their major surface protein. This shape-shifting, called antigenic drift, is why influenza vaccines-which are designed to elicit antibodies matched to each year's circulating virus strains-must be reformulated annually.

30 Oct 2009

GPC establishes grants to expand knowledge about probiotics

Today, the success of the Young Investigator Grant for Probiotics Research (YIGPRO) program was confirmed with the announcement of two $50,000 grants that are available to rising young investigators in the field of probiotics. 2010 marks the third consecutive year for the grants. The grants were established by The Global Probiotics Council (GPC), a committee formed by DANONE and Yakult Honsha Co., Ltd., and are designed to contribute to the advancement of probiotics and gastrointestinal microbiota research in the United States.

30 Oct 2009

Viral protein could be a major player in SARS virulence

Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease. In the 2003 epidemic, for example, between 5 and 10 percent of those who fell sick from the SARS virus died, adding up to more than 900 fatalities worldwide.

30 Oct 2009

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons.

30 Oct 2009

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), the Australian Animal Health Laboratory (AAHL), and the National Cancer Institute (NCI), National Institutes of Health (NIH) reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

30 Oct 2009

Immune System News and Research

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Juvaris BioTherapeutics commences enrollment in its JVRS-100 influenza vaccine adjuvant study

Switching to new immunosuppressant drug may reduce skin cancer after kidney transplantation

WCMC-Q's biomedical research program makes significant progress

Bacteria use a well-studied communication system to resist antibiotics

Scientists report a major step forward in the development of an effective therapy against Nipah virus

Four abstracts on RSV and influenza prevention in pediatric health to be presented

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Immunotherapy, a new therapeutic area to destroy tumor cells

Women may need smaller dose of H1N1 vaccine

Research suggests the possibility of an effective treatment for Hendra virus infections in humans

Public concern can undermine flu vaccination campaigns

Recent releases in Global Health

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

Scientists present new perspective on antigenic drift of flu viruses

GPC establishes grants to expand knowledge about probiotics

Viral protein could be a major player in SARS virulence

Helper T cell's effect raises possibility of cellular therapy and vaccine development

Risk of serious flu-related sickness far outpaces risk of injectable vaccine in pregnant women

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News